All deliverables
Video & Motion · HCPs · ABPI Regulated

Animated MOA.
The mechanism made visible. The production brief made simple.

Audience
HCPs
Output
Storyboard + motion spec + VO script
Compliance
ABPI 2024
Price from
£310

The complete production package for an animation studio.

The Animated MOA deliverable from Spectrum& is not a finished video file — it's the complete production package that enables an animation studio to produce the finished video accurately and efficiently. This includes an annotated scene-by-scene storyboard, a motion design specification, and a timed VO script.

Flux and Medi work in close collaboration. Every visual direction note in the storyboard is scientifically annotated: the mechanism being illustrated, the primary reference supporting it, and any specific notation from the SmPC. There is no scene in the storyboard that Medi hasn't verified.

For regulated HCP-facing MOAs, Reg reviews the completed storyboard and VO script against ABPI 2024. Comparative mechanism scenes — which are common in complex MOAs — receive particular scrutiny. No animation brief leaves Spectrum& with unresolved compliance findings.

The team behind it.

Core team shown. Complexity tier determines which additional specialists are activated.

Simple, Medium, or Complex — you choose the depth.

Simple Medium Complex
Scope Linear MOA · 4–6 scenes Branching pathway · receptor detail · 8–10 scenes Full mechanism · cell-level · comparator MOA · 15+ scenes
Team Sys, Medi, Flux, Aria, Pace Same team, greater depth + Reg
Price range ~£310 ~£590 ~£1,200
Best for Product launch, simple mechanism, one pathway Specialist HCP audience, receptor-level detail Full class comparison, multi-pathway mechanism, congress KOL use

What it looks like.

MOA Storyboard (Simple) — production document
Verixtol® (verixtumab) — MOA Storyboard
Linear MOA · 6 scenes · ~90 seconds · HCP audience
Scene 10:00–0:15
Visual: Wide shot of skin cross-section; dermal layer highlighted
VO: "In plaque psoriasis, a dysregulated immune response drives chronic inflammation in the skin."
On-screen: "Plaque psoriasis — a chronic immune-mediated condition"
FLUX: Recommend epidermis/dermis layers labelled. Medi confirms anatomy.
Scene 30:30–0:50
Visual: IL-17A molecule zoomed in; verixtumab antibody shown binding to IL-17A
VO: "Verixtumab binds selectively to IL-17A, neutralising it before it can activate keratinocytes."
On-screen: "Selective IL-17A neutralisation"
MOA Storyboard (Medium) — receptor detail
Verixtol® — Branching Pathway MOA (IL-17A + receptor detail)
10 scenes · ~2:30 · Receptor-level detail · HCP specialist audience
Scene 5 — IL-17RA/RC receptor complex1:10–1:35
Visual: Keratinocyte surface rendered; IL-17RA and IL-17RC receptor subunits shown as distinct structures; IL-17A approaches and binds both subunits to form active signalling complex
VO: "IL-17A exerts its pro-inflammatory effects by binding a receptor complex consisting of two subunits — IL-17RA and IL-17RC — on the surface of keratinocytes."
On-screen: "IL-17RA · IL-17RC receptor complex"
MEDI: IL-17RA and IL-17RC subunit nomenclature confirmed — consistent with SmPC Section 5.1 and Hu et al, J Immunol 2022. Animation must distinguish the two receptor subunits visually.
MOA Storyboard (Complex) — comparator scene
Verixtol® — Full Mechanism with Comparator MOA
16 scenes · ~4 minutes · Cell-level · Comparator IL-17A vs IL-17A/F mechanism
Scene 12 — Comparator MOA (IL-17A/F dual inhibition)2:45–3:20
Visual: Split screen — left panel shows verixtumab selectively binding IL-17A only; right panel shows bimekizumab binding both IL-17A and IL-17F
VO: "Unlike bimekizumab, which inhibits both IL-17A and IL-17F, verixtumab selectively targets IL-17A. This distinction may be relevant in patients with a history of inflammatory bowel disease, where IL-17F inhibition has been implicated in mucosal integrity."
On-screen: "Selective IL-17A vs dual IL-17A/F inhibition — mechanism comparison"
REG CHECK: Comparative mechanism claim — must include fair balance statement. Ensure VO is balanced and cites referenced mechanism data. Not a superiority claim — mechanism distinction only. Reg to approve scene 12 copy before production brief issued.

Full rendered examples will be available at launch.

ABPI 2024 Compliance

All HCP-facing Animated MOA storyboards are subject to ABPI 2024 compliance review. Comparative mechanism claims are reviewed with particular care. Reg generates the MLR reference pack for the storyboard — matching what the final video will be reviewed against.

Start your Animated MOA.

Tell us about your brief. We'll assemble the right team and get started today.

Start a project →